Please login to the form below

Not currently logged in

Sanofi appoints Meeker CEO of Genzyme

Current chief operating officer of Genzyme, David Meeker, will take over as CEO of the company from November 1

Current chief operating officer of Genzyme, David Meeker, will take over as CEO of the company from November 1.

He was appointed by France-based pharmaceutical company Sanofi who purchased Genzyme in April 2011 for about $20bn.

Former Genzyme CEO, Henri A Termeer, who had spent 26 years in the position, left Genzyme following the takeover. The company had since been without a CEO until Meeker's appointment.

Christopher A Viehbacher, CEO of Sanofi, said: "After working closely with David over the past six months, I am confident that he is the best person to lead Genzyme. David's commitment to employees, physicians and patients has been a key success factor in the successful integration of Genzyme as part of the Sanofi Group."

Under Meeker's leadership, Genzyme will incorporate the rare disease business and the multiple sclerosis franchise.

Previous Genzyme divisions - renal, biosurgery and oncology - have been integrated within the existing Sanofi portfolio.

Meeker joined Genzyme in 1994 as medical director to work on the cystic fibrosis gene therapy programme. Other positions Meeker held at Genzyme include president of the global rare disease business.

25th October 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Beyond the event
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...